← Back to patent-cliff list
1.0% povidone-iodine ophthalmic gel sterile solution (IVIEW Therapeutics)
Tier C — Watch / trade1.0% povidone-iodine ophthalmic gel sterile solution (IVIEW Therapeutics)
Iview Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Bacterial proteins
Indications (approved)：Keratitis, 细菌性结膜炎, 病毒性结膜炎, 腺病毒感染
Regional status
US
-
EU
-
China
Phase II
2022-01-06
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of 1.0% povidone-iodine ophthalmic gel sterile solution (IVIEW Therapeutics)?
Approved indications include: Keratitis, 细菌性结膜炎, 病毒性结膜炎, 腺病毒感染.
When does the 1.0% povidone-iodine ophthalmic gel sterile solution (IVIEW Therapeutics) patent expire?
No public expiry year is available for 1.0% povidone-iodine ophthalmic gel sterile solution (IVIEW Therapeutics) yet; this page updates once verified.
How do I get a quote for 1.0% povidone-iodine ophthalmic gel sterile solution (IVIEW Therapeutics) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05